Fast cars, food and wine, music and the arts – and chemistry – are Stephen Munk’s passions. To feed one of these passions he has been President and CEO of Ash Stevens, headquartered in the US automobile and Motown city of Detroit, Michigan for the past 15 years.
Under his direction, the company has become a leading provider of high-calibre chemical development research for drug substances.
Ash Stevens has more than 50 years of experience developing and manufacturing active pharmaceutical ingredients (APIs) for new cancer drugs and other therapeutic agents and is a long-time provider of contract research services to several Institutes within the US National Institutes of Health, including the National Cancer Institute and the Walter Reed Army Institute of Research.
When Munk joined the firm in 1997 there were 35 staff and it had received two FDA manufacturing approvals. He became President in 1998, adding the title of CEO in 2001. Ash Stevens has since taken its FDA approvals to 12 and staffing levels have more than doubled to nearly 80 people, with new positions available.
‘Since I joined we have been investing and growing and my proudest achievement has been to move an outstanding but academic chemistry laboratory into a functional API manufacturing organisation,’ he says.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.